Trim UNH 20-25% to 75-80% residual; add protective puts, preserve franchise floor
The 20-25% trim (75-80% residual) sits outside both failure modes identified in the 09-03 and 09-04 lessons — light enough to preserve franchise optionality (0.62 defensive beta, $24.3B TTM FCF, A-rated balance sheet with $28.1B cash, 2.4% dividend yield) if Q3 confirms recovery, heavy enough to capture meaningful alpha if Q3 disappoints. The defined-size reduction with immediate execution applies the binding 09-10 corrective rather than replicating the alpha-destructive passive Hold pattern.
| Position | Action |
|---|---|
| Current position at full weight | Trim 20-25% immediately to leave 75-80% residual |
| Residual position held through Q3 catalyst | Add $345-350 strike January 2027 protective put (~1.5-2% of residual notional) as tail insurance |
| Position at 75-80% residual | Maintain $348 hard stop at 200 SMA structural level (~2 points cushion above $350.80 SMA) |
| Bear case trigger: Close <$385 OR weekly close <$350 OR MLR spike on Q3 OR guidance cut | Downgrade to Sell with additional 30% trim (50% residual) plus $380 puts hedge on residual |
UNH offers an asymmetric risk-reward setup: a V-shaped earnings recovery already confirmed, 16.9x forward P/E (cheaper than S&P 500 at 21x), a vertically-integrated Optum moat, $24B in annual FCF, and a loaded 60-90 day catalyst pipeline — all priced as if the stock is broken.
| Indicator | Value | Signal |
|---|---|---|
| close_50_sma | 409.17 | bearish |
| close_200_sma | 350.80 | bullish |
| close_10_ema | 392.33 | bearish |
| rsi | 35.48 | bearish |
| macd | -4.61 | bearish |
| macd_signal | -4.07 | bearish |
| atr | 10.86 | neutral |
| bollinger_lower_band | 382.15 | bearish |
Support: 350.8 · 382.15 · 305 · 312 | Resistance: 392.33 · 394.2 · 409.17 · 415 · 420
UNH is in a confirmed short-term downtrend with all momentum oscillators aligned bearishly and price stretched below its lower Bollinger band. The 200 SMA at $350.80 is the critical line in the sand — holding it preserves the structural bull case; losing it would invalidate the broader uptrend and open a much deeper drawdown zone toward $305–312. The final transaction proposal is HOLD, as long-term trend remains intact above the 200 SMA while tactical trend is bearish but stretched, making a fresh sell premature and a fresh buy unconfirmed.
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Base case: range $385-$405
Then: Maintain Underweight at 75-80% residual
UNH earns its premium multiple through Optum's vertically-integrated moat
↩ rebuts: “Bear claims UNH has a premium multiple with slowest peer growth — the forward P/E is actually a discount to the S&P 500, and the premium reflects the Optum moat, not overvaluation.”
EV: +11% (base case to $420), +33% (bull case to $504) · concedes: Revenue growth decelerated to 0.4% YoY in Q2-26 (though this reflects a mature, $450B-revenue franchise profile, not structural failure); Short-term technicals are bearish (price below 10 EMA, below 50 SMA, MACD rolled over, RSI at 35.48); Q4-2025 was a genuine earnings catastrophe (Net Income $0.01B) from Change Healthcare cyberattack, MLR repricing, and MA risk-adjustment write-downs; Bear case shows -5% downside to $360 if multiple compresses on macro headwinds
UNH's recovery is fragile and unproven, trading at a premium multiple (24.35x trailing P/E) for the slowest-growing peer, with broken technicals, binary catalyst risks, and macro headwinds that make the current valuation asymmetrically dangerous to the downside.
EV: -$288 (-24% from current levels) · concedes: The bull correctly identifies that Q4-2025 was a catastrophic one-time event; The dividend yield of 2.4% provides some income support; UNH is a $450B franchise with significant scale; Net debt reduction ($9.3B over 9 months) does strengthen the balance sheet; Q3-2026 earnings could be a 'clean print' if MLR cooperates
→ vs conservative: Waiting for Q3 confirmation means buying at $410-420 after 15-20% rally from lows; investing before catalyst is the point, not after
→ vs conservative: 'Broken technicals in confirmed fundamental uptrend ARE the entry' - the conservative view is 'technically correct but practically backwards'
→ vs neutral: Missing asymmetric risk-reward: Trailing P/E 24.35x vs forward P/E 16.9x gap is not noise, it's 44% earnings recovery priced in
→ vs conservative: The 'broken technicals don't support adding' argument ignores $24B FCF, $73B declining debt, and management guidance reaffirming turnaround
→ vs conservative: Stop at $348 gets shaken out by routine volatility on name with $10.86 ATR; April 2026 breakout zone at $305-312 is the real structural floor
→ vs conservative: Waiting for technical reversal below $365 ignores that 200 SMA at $350.80 has held decisively and acts as structural floor
Market Cap
$340.3 B
Share Price
~$379
52-Week High
$461.62
52-Week Low
$255.97
50-Day MA
$410.12
200-Day MA
$352.73
P/E (TTM)
24.35x
Forward P/E
16.90x
PEG Ratio
1.07
P/B
3.48x
Beta
0.62
Dividend Yield
2.39%
EPS (TTM)
$15.57
Forward EPS
$22.44
Revenue TTM
$450.5 B
Revenue Growth Q2-26 YoY
+0.4%
Gross Margin TTM
19.7%
Operating Margin TTM
7.13%
Net Margin TTM
3.14%
ROE
14.15%
ROA
4.87%
EBITDA TTM
$26.7 B
Total Assets
$309.7 B
Total Debt
$73.3 B
Net Debt
$44.7 B
Stockholders' Equity
$98.4 B
Goodwill
$110.6 B
Debt/Capitalization
42.7%
Free Cash Flow TTM
$24.3 B
Operating CF Q2-26
$11.05 B
CapEx Q2-26
$0.80 B
Q2-26 Dividends
$2.09 B
Q2-26 Buybacks
$1.65 B
Q2-26 Debt Paydown
$4.41 B
Q2-2026 Revenue
$112.03 B
Q2-2026 Net Income
$5.48 B
Q2-2026 Diluted EPS
$6.04
Q1-2026 Net Income
$6.28 B
Q1-2026 Diluted EPS
$6.90
Strengths
Concerns
UNH is the largest diversified managed healthcare company in the U.S., operating through UnitedHealthcare (health benefit plans) and Optum (health services including care delivery, analytics, and pharmacy benefit management). The company faced a catastrophic Q4-2025 (EPS collapsed to $0.01 from Change Healthcare cyberattack settlement and MLR repricing) but has delivered a V-shaped recovery with Q1/Q2-2026 net income of $6.28B and $5.48B respectively. The valuation gap between trailing P/E (24.35x) and forward P/E (16.90x) suggests the market is pricing in EPS normalization to $22.44. UNH is aggressively deleveraging (debt cut $6.8B in 9 months), generating strong FCF ($24.3B TTM), and maintaining a 2.39% dividend yield with a 0.62 beta for defensive positioning. Key risks include decelerating revenue growth (only 0.4% YoY in Q2-2026), Medicare Advantage rate uncertainty, Star Ratings volatility, and elevated goodwill. For traders, the medium-term view is bullish with a mean-reversion target of $420-440, while using Q3-2026 earnings (mid-October) as the next major catalyst.
Macro: Rate path is the dominant macro story for managed-care equities. The next FOMC meeting is framed as a near-lock hike (IBD, Barron's), reinforced by gold rebounding toward $4,350 on CPI expectations. The 10-year Treasury is holding below 5% even after 'firm' August CPI data (WSJ). Polymarket prices 'No Fed rate cuts in 2026?' at 93% (~$8.25M volume, +0.3pp w/w); every '≥6 cuts' market is at 0%. Implied probability of any cuts this year is ~7%. Recession odds are benign at 7% for US by end of 2026 (+0.5pp w/w), UK/Japan at 5–6%. The hawkish rate framing is delivered into a soft-landing, not contraction, narrative. Note: FRED macro endpoints returned DATA_UNAVAILABLE this session; data sourced from news flow and Polymarket only.